| ID | 119129 |
| 著者 |
板東, 浩
Tokushima University|Medical Research|Japan Low Carbohydrate Diet Promotion Association|Kanaiso Hospital
KAKEN研究者をさがす
Kato, Y
Kanaiso Hospital
Yamashita, H
Kanaiso Hospital
Kato, Y
Kanaiso Hospital
Kawata, T
Kanaiso Hospital
|
| キーワード | Oral hypoglycemic agents (OHAs)
Imeglimin (Twymeeg)
Vildagliptin/Metformin (EquMet)
Trials of IMeglimin for Efficacy and Safety (TIMES)
Vildagliptin Efficacy in combination with metfoRmIn For early treatment of type 2 diabetes (VERIFY)
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | Background: Among several oral hypoglycemic agents (OHAs), Imeglimin (Twymeeg) and vildagliptin/metformin (EquMet) has been in focus.
Case presentation: The patient is 59-year-old female with obesity and type 2 diabetes (T2D). Result: For unstable HbA1c during 2022, EquMet was started and afterwards Twymeeg was added. HbA1c decrease was 0.4% in 4 months and 0.6% in 3 months, respectively. Discussion and Conclusion: Large studies of Twymeeg and EquMet were Trials of IMeglimin for Efficacy and Safety (TIMES), and Vildagliptin Efficacy in combination with metfoRmIn For early treatment of type 2 diabetes (VERIFY). Combined these treatments may bring more beneficial clinical efficacy. |
| 掲載誌名 |
SunText Review of Endocrine Care
|
| ISSN | 27715469
|
| 出版者 | SunText Reviews
|
| 巻 | 2
|
| 号 | 1
|
| 開始ページ | 108
|
| 発行日 | 2023-02-12
|
| 権利情報 | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
| 出版社版DOI | |
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
